{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02479698",
            "orgStudyIdInfo": {
                "id": "2014-0279"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2015-01264",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "2014-0279",
                    "type": "OTHER",
                    "domain": "M D Anderson Cancer Center"
                }
            ],
            "organization": {
                "fullName": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus",
            "officialTitle": "Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by Ex Vivo Expansion in Patients With BK Virus Infection and JC Virus Infection",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Rare Diseases",
                "Infectious Diseases",
                "Other"
            ],
            "study": "cytotoxic-t-lymphocytes-in-treating-patients-with-malignancies-with-bk-and-or-jc-virus"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2015-07-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-07-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2015-06-19",
            "studyFirstSubmitQcDate": "2015-06-23",
            "studyFirstPostDateStruct": {
                "date": "2015-06-24",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-07-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.",
            "detailedDescription": "PRIMARY OBJECTIVE:\n\nI. To assess the efficacy, feasibility and safety of administering most closely human leukocyte antigen (HLA)-matched BK specific cytotoxic T lymphocyte (CTL) lines (BK-CTLs) generated by ex vivo expansion to mediate antiviral activity in patients with any type of malignancies, and/or human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDs), and/or history of solid organ transplant with BK and JC infections.\n\nSECONDARY OBJECTIVE:\n\nI. To assess the persistence of the administered BK-CTLs generated by ex vivo expansion in patients with any type of malignancies, and/or HIV/AIDs, and/or history of solid organ transplant with BK and JC infections.\n\nOUTLINE:\n\nPatients receive allogeneic BK-specific cytotoxic T-lymphocytes intravenously (IV) over 30 minutes. Patients achieving partial response, stable disease, or progressive disease are eligible for 7 additional infusions of CTL occurring at least 2 weeks after the previous CTL infusion if they meet the eligibility criteria for subsequent therapy.\n\nAfter completion of study treatment, patients are followed up periodically for 12 months."
        },
        "conditionsModule": {
            "conditions": [
                "Acquired Immunodeficiency Syndrome",
                "BK Virus Infection",
                "Human Immunodeficiency Virus",
                "JC Virus Infection",
                "Malignant Neoplasm",
                "Merkel Cell Carcinoma",
                "Merkel Cell Polyomavirus Infection",
                "Viral Encephalitis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment (BK-specific cytotoxic T lymphocytes)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive allogeneic BK-specific cytotoxic T-lymphocytes IV over 30 minutes. Patients achieving partial response, stable disease, or progressive disease are eligible for 19 additional infusions of CTL occurring at least 2 weeks after the previous CTL infusion if they meet the eligibility criteria for subsequent therapy.",
                    "interventionNames": [
                        "Biological: Allogeneic BK-specific Cytotoxic T-lymphocytes",
                        "Other: Laboratory Biomarker Analysis"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Allogeneic BK-specific Cytotoxic T-lymphocytes",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Treatment (BK-specific cytotoxic T lymphocytes)"
                    ],
                    "otherNames": [
                        "Allogeneic BK-CTLs",
                        "Allogeneic BK-specific CTLs"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Laboratory Biomarker Analysis",
                    "description": "Correlative studies",
                    "armGroupLabels": [
                        "Treatment (BK-specific cytotoxic T lymphocytes)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Response, defined as response (R) = (best response [R1] or second best response [R2])",
                    "description": "The method of Thall et al will be used to monitor the probabilities of response.",
                    "timeFrame": "Up to 56 days"
                },
                {
                    "measure": "Incidence of acute graft-versus-host disease (GVHD)",
                    "description": "The method of Thall et al will be used to monitor the probabilities of grade 3 or 4 GVHD.",
                    "timeFrame": "Within 28 days of the last dose of cytotoxic T lymphocytes (CTLs)"
                },
                {
                    "measure": "Incidence of adverse events",
                    "description": "Will be continuously monitored.",
                    "timeFrame": "Up to day 100"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall survival",
                    "description": "Each outcome will be evaluated by tabulation and by fitting a Bayesian statistical regression model for binary outcomes as a function of covar. Unadjusted event time distributions will be estimated using the Kaplan-Meier method.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Glomerular filtration rate",
                    "description": "Each outcome will be evaluated by tabulation and by fitting a Bayesian statistical regression model for binary outcomes as a function of covar. Unadjusted event time distributions will be estimated using the Kaplan-Meier method.",
                    "timeFrame": "Up to 12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with any type of malignancies; and/or HIV/AIDs; and/or history of solid organ transplant; and/or Merkel polyoma-virus related Merkel cell tumor(s) with measurable disease on imaging per Response Evaluation Criteria in Solid Tumors (RECIST) criteria\n* Patients with microscopic hematuria OR biopsy proven BK nephritis and urine or blood polymerase chain reaction (PCR) positive for BK virus and/or JC viral encephalitis\n* Clinical status at enrollment to allow tapering of steroids to less than 0.5 mg/kg/day of prednisone\n* Patients who are currently receiving treatment with cidofovir, leflunomide, or other antiviral therapy with no response, will be eligible for CTL infusion\n* Once patients have completed 6-week safety and efficacy assessments after completion of the last anti-BK CTL infusion, patients will be eligible for enrollment on other supportive care protocols\n* Written informed consent from patient and/or signed assent from patient, parent or guardian\n* Negative pregnancy test in female patients of childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization; women of child bearing potential must be willing to use an effective contraceptive measure while on study\n\nExclusion Criteria:\n\n* Patients receiving prednisone \\> 0.5 mg/kg/day at time of enrollment, or have received anti-thymocyte globulin (ATG) within 14 days or have received donor lymphocyte infusion (DLI) or Campath within 28 days of enrollment\n* Patients with other uncontrolled infections (except HIV/AIDS); for bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment; for fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment; progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection; persisting fever without other signs or symptoms will not be interpreted as progressing infection\n* Patients with active acute graft-versus-host disease (GVHD) grades II-IV",
            "healthyVolunteers": false,
            "sex": "ALL",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Amanda L. Olson, MD",
                    "role": "CONTACT",
                    "phone": "713-792-8750",
                    "email": "ALOlson@mdanderson.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Amanda Olson",
                    "affiliation": "M.D. Anderson Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "M D Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amanda Olson",
                            "role": "CONTACT",
                            "phone": "713-792-8750"
                        },
                        {
                            "name": "Amanda Olson",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "33929874",
                    "type": "DERIVED",
                    "citation": "Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021 Aug 20;39(24):2710-2719. doi: 10.1200/JCO.20.02608. Epub 2021 Apr 30. Erratum In: J Clin Oncol. 2023 Oct 20;41(30):4826. doi: 10.1200/JCO.23.01860."
                },
                {
                    "pmid": "30304652",
                    "type": "DERIVED",
                    "citation": "Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, Chi TL, Ferrajoli A, Kaur I, Li L, Champlin R, Shpall EJ, Rezvani K. Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. N Engl J Med. 2018 Oct 11;379(15):1443-1451. doi: 10.1056/NEJMoa1801540."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "University of Texas MD Anderson Cancer Center Website",
                    "url": "http://www.mdanderson.org"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000003141",
                    "term": "Communicable Diseases"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000000163",
                    "term": "Acquired Immunodeficiency Syndrome"
                },
                {
                    "id": "D000015658",
                    "term": "HIV Infections"
                },
                {
                    "id": "D000015266",
                    "term": "Carcinoma, Merkel Cell"
                },
                {
                    "id": "D000018792",
                    "term": "Encephalitis, Viral"
                },
                {
                    "id": "D000027601",
                    "term": "Polyomavirus Infections"
                },
                {
                    "id": "D000004660",
                    "term": "Encephalitis"
                },
                {
                    "id": "D000007153",
                    "term": "Immunologic Deficiency Syndromes"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000086982",
                    "term": "Blood-Borne Infections"
                },
                {
                    "id": "D000015229",
                    "term": "Sexually Transmitted Diseases, Viral"
                },
                {
                    "id": "D000012749",
                    "term": "Sexually Transmitted Diseases"
                },
                {
                    "id": "D000016180",
                    "term": "Lentivirus Infections"
                },
                {
                    "id": "D000012192",
                    "term": "Retroviridae Infections"
                },
                {
                    "id": "D000012327",
                    "term": "RNA Virus Infections"
                },
                {
                    "id": "D000012897",
                    "term": "Slow Virus Diseases"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000090862",
                    "term": "Neuroinflammatory Diseases"
                },
                {
                    "id": "D000004266",
                    "term": "DNA Virus Infections"
                },
                {
                    "id": "D000014412",
                    "term": "Tumor Virus Infections"
                },
                {
                    "id": "D000018278",
                    "term": "Carcinoma, Neuroendocrine"
                },
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                },
                {
                    "id": "D000020805",
                    "term": "Central Nervous System Viral Diseases"
                },
                {
                    "id": "D000002494",
                    "term": "Central Nervous System Infections"
                },
                {
                    "id": "D000069544",
                    "term": "Infectious Encephalitis"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M3522",
                    "name": "Acquired Immunodeficiency Syndrome",
                    "asFound": "Acquired Immunodeficiency Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18250",
                    "name": "HIV Infections",
                    "asFound": "Acquired Immunodeficiency Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "asFound": "Infection",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "asFound": "Infection",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10199",
                    "name": "Immunologic Deficiency Syndromes",
                    "asFound": "Immunodeficiency",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7825",
                    "name": "Encephalitis",
                    "asFound": "Encephalitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "asFound": "Virus Infection",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17967",
                    "name": "Carcinoma, Merkel Cell",
                    "asFound": "Merkel Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20851",
                    "name": "Encephalitis, Viral",
                    "asFound": "Viral Encephalitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M23236",
                    "name": "Polyomavirus Infections",
                    "asFound": "Polyomavirus Infections",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2593",
                    "name": "Blood-Borne Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15558",
                    "name": "Sexually Transmitted Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17933",
                    "name": "Sexually Transmitted Diseases, Viral",
                    "relevance": "LOW"
                },
                {
                    "id": "M18640",
                    "name": "Lentivirus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15026",
                    "name": "Retroviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15149",
                    "name": "RNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15700",
                    "name": "Slow Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2803",
                    "name": "Neuroinflammatory Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7442",
                    "name": "DNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M17162",
                    "name": "Tumor Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M20423",
                    "name": "Carcinoma, Neuroendocrine",
                    "relevance": "LOW"
                },
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M22560",
                    "name": "Central Nervous System Viral Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5743",
                    "name": "Central Nervous System Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M457",
                    "name": "Infectious Encephalitis",
                    "relevance": "LOW"
                },
                {
                    "id": "T3716",
                    "name": "Merkel Cell Carcinoma",
                    "asFound": "Merkel Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}